Important note

This AI stock analysis for Johnson & Johnson is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Johnson & Johnson - AI Stock Analysis

Analysis generated March 10, 2025

Johnson & Johnson, founded in 1886, is a global leader in the pharmaceuticals, medical devices, and consumer health products sectors. With a broad range of products, from consumer health items like baby products and Band-Aids to complex pharmaceuticals and medical devices, the company has a well-diversified revenue base. Its substantial market presence and brand value contribute to its status as a blue-chip stock.

Fundamental Analysis

In the most recent fiscal quarter, Johnson & Johnson reported revenue of $22.3 billion. This marks a slight decrease of 0.73% from the previous quarter, indicating potential volatility. However, on a year-over-year basis, revenue increased by 4.26%, highlighting sustained long-term growth.

The company's net income for the quarter stood at $3.43 billion, an impressive 27.36% increase from the previous quarter, signaling improved profitability. However, there was a year-over-year decline of 15.26%, raising some concerns about the long-term consistency of its earnings.

EBITDA for the quarter was $18.9 billion, showing a staggering 276.06% increase from the prior quarter and a 216.02% year-over-year rise. This robust growth in EBITDA suggests significant operational efficiencies and strong performance across its business segments.

On the valuation front, Johnson & Johnson's current P/E ratio is 28.84. This high P/E ratio may indicate that the stock is overvalued, which could be a bearish signal. Additionally, insider selling observed in the past couple of months adds a layer of caution for potential investors.

Technical Analysis

The current stock price for Johnson & Johnson is $167.33. There has been a positive short-term trend, with the stock price increasing by 9.35% over the past month. The long-term trend also looks favorable, with a 7.13% increase over the past year.

The stock's 10-day Simple Moving Average (SMA10) is at 166.11, edging higher than the previous SMA10 of 165.88, indicating a potential upward trend. The Relative Strength Index (RSI) is at 16.7, which typically denotes an oversold condition, implying a possible bullish trend in the near future.

Alternative Data Analysis

From an alternative data standpoint, Johnson & Johnson has 1,130 open job positions, a significant 22% increase in recent months. This is a positive sign, indicating the company's plans for growth and expansion.

Website traffic estimates show around 2.5 million visitors, with a 15% increase in recent months, suggesting improving customer acquisition. However, social media engagement metrics are mixed. While Instagram followers stand steady at 100,000, Twitter followers remain at 250,000 with no meaningful increase or decrease, indicating a neutral trend in customer engagement.

The AltIndex AI score for Johnson & Johnson is 44, indicating a 'Hold' recommendation. This score integrates fundamental, technical, and alternative data for a comprehensive outlook.

Conclusion and Recommendation

In summary, Johnson & Johnson shows a mixed set of indicators. The company's long-term revenue growth and substantial operational efficiencies are positive signs. However, the high P/E ratio and recent insider selling may indicate caution. Technical indicators suggest a potentially bullish trend in the near term, reinforced by a substantial increase in job postings and web traffic.

Based on the comprehensive analysis, a 'Hold' recommendation appears most prudent. While long-term growth prospects remain intact, short-term volatility and market valuation warrants a cautious approach.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.